- Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion Bloomberg
- GSK’s $500M Mega-Deal Unlocks 12 New Medicines: Major COPD Breakthrough in Pipeline Stock Titan
- Jiangsu Hengrui Pharma stock spikes 10% to 4-year high on drug development deal with GSK – here’s what the company does Mint
- GSK pays $500M upfront for rights to series of Hengrui drugs statnews.com
- GSK strengthens COPD offering via $12B biobucks, 12-program deal with China’s Hengrui Pharma Fierce Biotech
Source link
